Early Phase 1 N=6 Ketamine for Depression Relapse Prevention Following ECT
Depression
Primary: Completion Rate for Randomised Treatment — 0; 0 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=110 A Randomized Controlled Clinical Trial of Thymoglobulin® After Liver Transplantation
Liver Failure
Primary: The Incidence of Acute Kidney Injury (AKI) as Assessed by Change in Serum Creatinine From Baseline to 30 Days Post-transplant — .01; .06 mg/dL
N/A N=12 A Clinical Pilot Study of Newly Developed Ostomy Tapes and How They Adhere to the Skin
Stoma Site Leakage
Primary: Mean Adherent Area Measured by Photo of Used Tape — 46.54; 51.61; 52.94 Cm2
N/A N=88 Surgery or Lifestyle With Intensive Medical Management in the Treatment of Type 2 Diabetes
Type 2 Diabetes Mellitus · Obesity
Primary: Fasting Plasma Glucose <126 mg/dL and HbA1c < 6.5% at Three Years of Follow-up. — 13; 5; 42; 0 % of patients — p=0.60
N/A N=752 A Single Arm Trial With Resolute Onyx in ONE-Month DAPT for High-Bleeding Risk Patients Who Are Considered One-Month Clear (Onyx ONE Clear)
Coronary Artery Disease
Primary: Composite Endpoint: Number of Participants With Cardiac Death and Myocardial Infarction — 104 Participants
Phase 2 N=28 Expansion Trial for Axitinib In Head And Neck Cancer
Squamous Cell Carcinoma of the Head and Neck
Primary: Number of Evaluable Patients Alive at 6 Months — 71 percentage of participants
N/A N=57 Music Therapy Versus Control for Total Knee Arthroplasty
Arthroplasty, Replacement, Knee
Primary: Patient Satisfaction — 4.48 score on a scale
Phase 2 N=25 Study of Ribociclib With Everolimus + Exemestane in HR+ HER2- Locally Advanced/Metastatic Breast Cancer Post Progression on CDK 4/6 Inhibitor.
Breast Cancer
Primary: Participants With Dose Limiting Toxicities by Preferred Term in Cycle 1 (28 Days) - in Phase I — 1; 1; 0; 0 Participants
N/A N=98 Prospective Randomized Evaluation of a Two and Three Piece Total Ankle Replacement
Ankle Osteoarthritis
Primary: Pain Following a Total Ankle Replacement as Measured by the Visual Analog Scale (VAS) for Pain — 67.0; 71.3; 16.7; 18.6 mm — p=0.29
N/A N=100 Assessment of Novel Intraocular Injection Guide
Retinal Disease
Primary: Visual Analogue Scale (VAS) — 14; 33 mm on the VAS
Phase 3 N=313 DETERMINE-reduced - Dapagliflozin Effect on Exercise Capacity Using a 6-minute Walk Test in Patients With Heart Failure With Reduced Ejection Fraction
Heart Failure With Reduced Ejection Fraction (HFrEF)
Primary: Change From Baseline in Kansas-City Cardiomyopathy Questionnaire-Total Symptom Score (KCCQ-TSS) at Week 16 (Higher Scores Represent Less HF Symptom Frequency and…
Phase 4 N=20 Cryoanalgesia vs. Epidural in the Nuss Procedure
Pectus Excavatum · Funnel Chest
Primary: Length of Hospitalization — 3; 5 Length of Stay (Post-Operative Days)
Phase 2 N=49 Anesthetics to Prevent Lung Injury in Cardiac Surgery
Inflammatory Lung Injury · Ischemia-Reperfusion Lung Injury · Postoperative Pulmonary Complications
Primary: Bronchoalveolar Lavage (BAL) Concentration of TNF Alpha (pg/mL) — 0.53; 0.53; 22.06; 102.04 pg/mL
N/A N=115 Zenith TX2® Post-market Approval Study
Descending Thoracic Aortic Aneurysm
Primary: Number of Participants With Freedom From Thoracic Aortic Aneurysm-related Mortality — 114 Participants
Phase 2 N=9 Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma
Recurrent Follicular Lymphoma · Recurrent Mantle Cell Lymphoma · Recurrent Marginal Zone Lymphoma
Primary: Phase I: The Maximum Tolerated Dose (MTD) of Temsirolimus in Combination With Bortezomib, Rituximab and Dexamethasone — NA; NA mg